Insider buying last 90 days
No open-market insider purchases were filed for VOR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every VOR insider filing, plotted on the chart in Gekko.Open VOR in Gekko
NASDAQ: VOR
Vor Biopharma (VOR) Stock Analysis & Forecast
Oct 12 close
$19.80−0.10 (−0.5%)
Gekko Brief
AI summaryOct 12 closeVor Biopharma draws attention this week after releasing a post hoc analysis of its Phase 3 gMG trial for telitacicept, with commentary highlighting strong response depth, durability, and a consistent safety profile. A separate note on the stock's broader profile points to the company's focus on autoimmune disease therapies and its performance against the S&P 500. A Form 4 filing from 5 October was also noted as an administrative disclosure.
VOR closes at $19.80, down 0.5%, sitting between its 50-day average of $21.84 and 200-day average of $16.92, a mixed trend picture. Over the past month the stock is down 11.2%, though it remains up 7% over three months and 24% over six months, while the one-year return stands at -37.6%. The GekkoIndex reads 60.2, placing the stock in the Accumulation zone, down 6 points over five sessions. Price sits 42.9% below the Gekko Fair Value of $34.65.
The next earnings date falls on 12 November, 30 days out, beyond a typical 20-trading-day hold; the last report on 11 August showed an EPS of -0.80 against a -0.69 estimate, with a -4.4% reaction, and the company has beaten estimates in 3 of 8 quarters. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over five years shows a 5.6% average 20-day move from this point, rising in 3 of those years. Analyst coverage from 6 firms shows 5 buy ratings and 1 hold, with a consensus target of $39 and consensus upside of 97%.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Vor Biopharma price vs fair value
Close $19.80200-day averageGekko Fair Value $34.65
Vor Biopharma quick facts
- Market cap
- $1.07B
- P/E ratio
- 0.1
- Forward P/E
- —
- EPS, TTM
- $180.18
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.78
- Volume
- 867,375 avg 1.37M
- 1-year return
- −37.6%
- Typical daily move
- ±6.7%
- Typical 20-day move
- ±15.1%
- 50-day average
- $21.84
- 200-day average
- $16.92
- Next earnings
- Nov 12
- Shares outstanding
- 59.16M
Vor Biopharma swing-trade checklist
Vor Biopharma scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $19.80 sits between the 50-day ($21.84) and 200-day ($16.92) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60.2, Accumulation
Reading 60.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
42.9% below
Price is 42.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 31 days
Next report Nov 12, 2026, 31 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.6% on average
From this point in the calendar, the next 20 trading days averaged +5.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Vor Biopharma stock chart and price history
Vor Biopharma closed at $19.80 on Oct 12, 2026, −37.6% over the past year, inside a 52-week range of $6.50 to $33.50.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −11.2%
- 3 months
- +7.0%
- 6 months
- +24.0%
- 1 year
- −37.6%
The full VOR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open VOR in Gekko
Follow Vor Biopharma through every session
Put VOR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track VOR in GekkoFree for 7 days. No credit card required.
About Vor Biopharma
Vor Biopharma works on experimental cell-based treatments for cancer patients, built around engineered hematopoietic stem cells. Its furthest-along candidate, VOR33, is in Phase 1/2 trials and is being studied for acute myeloid leukemia and other blood cancers. These stem cells are modified to lack the CD33 protein, a marker typically present on AML cancer cells, which is central to how the therapy is meant to work.
Beyond VOR33, the company has built a broader platform of engineered stem cells intended to support multiple approaches to blood cancer treatment, including CAR-T therapies, bispecific antibodies, and antibody-drug conjugates. To support manufacturing needs, Vor Biopharma works with Akron BioProducts on producing cGMP-grade nucleases used in its development process.
The company was founded in 2015 and is headquartered in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker VOR.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- vorbio.com
Vor Biopharma GekkoIndex: the smart money zone
Vor Biopharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.2, in the Accumulation zone, down 6 points over five sessions.
60.2Accumulation
Down 6 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 91 | Not available | |||
| Accumulation (current zone) | 251 | +3.8% | +47.2% | ||
| Neutral | 308 | +1.4% | −0.3% | ||
| Distribution | 27 | +4.8% | +12.2% | ||
| Selling | 5 | Too few readings yet | |||
Average VOR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the VOR price, zone by zone.Track VOR in Gekko
Is Vor Biopharma stock overvalued? Gekko Fair Value
Vor Biopharma trades 42.9% below Gekko Fair Value of $34.65, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Vor Biopharma shares are worth, recalculated every trading day.
$34.65
Gekko Fair Value, Oct 10, 2026
42.9% Undervalued
At the end of Aug 2026 the price was 36.6% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open VOR in Gekko
Vor Biopharma insider and Congress trading
No open-market insider purchases were filed for Vor Biopharma, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in VOR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for VOR, plotted on the chart in Gekko.Open VOR in Gekko
Buybacks
Vor Biopharma has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $4K
- As a share of market cap
- 0.00%
From company filings.
Vor Biopharma earnings: next date and track record
Vor Biopharma reports on Nov 12, 2026 (31 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 12, 2026
31 days away
- EPS estimate
- −$0.82
3 of 8reports beat the EPS estimate
±6.9%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$0.80 est −$0.69 | — | −4.4% |
| May 13, 2026 | −$0.73 est −$0.78 | — | −8.5% |
| Mar 30, 2026 | $307.53 est −$1.19 | — | +23.2% |
| Dec 31, 2025 | $307.53 est −$1.19 | — | −7.1% |
| Nov 13, 2025 | −$121.60 est −$0.10 | — | −0.5% |
| Aug 12, 2025 | −$251.24 est −$0.22 | — | +1.5% |
| May 14, 2025 | −$5.20 est −$4.16 | — | +6.9% |
| Mar 20, 2025 | −$0.44 est −$0.31 | — | +3.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Vor Biopharma stock forecast and analyst price targets
Analysts’ average 12-month price target for Vor Biopharma is $39.00, +97.0% from the last close, from 6 firms rating the stock in the last 90 days.
$39.00consensus 12-month target, +97.0% from the last close
Now $19.80Avg $39.00
Low $27High $50
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | Stifel Nicolaus | $40 | +102.0% |
| Sep 9 | Jefferies | $48 | +142.4% |
| Sep 9 | Citi | $50 | +152.5% |
| Aug 31 | Wells Fargo | $30 | +51.5% |
| Aug 13 | Citi | $50 | +152.5% |
+47.2%average 20-day move after past Accumulation readings
+5.6%average move over the next 20 trading days in the last 5 years
±6.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Vor Biopharma seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Vor Biopharma averaged +5.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.2% | 4 of 5 |
| Next 10 trading days | +1.1% | 3 of 5 |
| Next 15 trading days | +5.0% | 3 of 5 |
| Next 20 trading days | +5.6% | 3 of 5 |
| Next 30 trading days | −14.6% | 2 of 5 |
For scale, VOR’s typical 20-trading-day move in either direction is about 15.1%.
Vor Biopharma market cap and key statistics
Vor Biopharma’s market cap is $1.07B, with a P/E ratio of 0.1 and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.07B
- P/E ratio
- 0.1
- EPS, TTM
- $180.18
- Gekko Fair Value
- $34.65
Trading
- Volume
- 867,375
- Avg volume, 20 days
- 1.37M
- 52-week high
- $33.50
- 52-week low
- $6.50
- Shares outstanding
- 59.16M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -125.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.78
- Typical daily move
- ±6.7%
- Typical 20-day move
- ±15.1%
Vor Biopharma stock news this week
Coverage of Vor Biopharma this week reads neutral: 1 positive, 2 neutral and 0 negative headlines.
- Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw FocusYahoo Finance, Oct 8
- Vor Biopharma Inc. (VOR) stock price, news, quote and historyYahoo Finance Singapore, Oct 7
- Form 4 Vor Biopharma Inc For: 5 October By Investing.comInvesting.com Nigeria, Oct 6
Vor Biopharma peers
Vor Biopharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Vor Biopharma stock FAQ
What is Vor Biopharma’s market cap?
Vor Biopharma’s market cap is $1.07B at the Oct 12, 2026 close of $19.80, with 59.16M shares outstanding. The shares trade on a P/E ratio of 0.1.
What is the Vor Biopharma stock forecast?
The consensus analyst 12-month price target for Vor Biopharma is $39.00, +97.0% from the last close. Of the 6 firms that rated the stock in the last 90 days, 5 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Vor Biopharma stock overvalued or undervalued?
On Gekko’s estimate Vor Biopharma is undervalued: the Oct 12, 2026 close of $19.80 is 42.9% below Gekko Fair Value of $34.65. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Vor Biopharma report earnings next?
Vor Biopharma is expected to report on Nov 12, 2026 (31 days away). Analysts expect earnings of −$0.82 per share. Vor Biopharma beat the earnings estimate in 3 of its last 8 reports, moving 6.9% on average across the report.
What is Vor Biopharma’s 52-week high and low?
Vor Biopharma’s 52-week high is $33.50 and its 52-week low is $6.50; it closed at $19.80 on Oct 12, 2026, −37.6% over the past year. Over the last five years the shares peaked at $370.20 on Nov 5, 2021.
Is Vor Biopharma stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Vor Biopharma the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.